A favorable outcome of intensive immunotherapies for new-onset refractory status epilepticus (NORSE)

A favorable outcome of intensive immunotherapies for new-onset refractory status epilepticus (NORSE)

Abstract Background New-onset refractory status epilepticus (NORSE) is a newly defined critical disease entity characterized by prolonged periods of refractory epileptic seizure with no readily identifiable cause in otherwise healthy individuals. Its etiology is uncertain, but autoimmune encephaliti...

Full description

Bibliographic Details
Main Authors: Satoshi Kodama, Noritoshi Arai, Akiyoshi Hagiwara, Akio Kimura, Sousuke Takeuchi
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Journal of Intensive Care
Subjects:
Status epilepticus
New-onset refractory status epilepticus (NORSE)
Immunotherapy
Autoimmune encephalitis
Plasma exchange (PE)
Intravenous immunoglobulin (IVIG)
Online Access:http://link.springer.com/article/10.1186/s40560-018-0315-7

Internet

http://link.springer.com/article/10.1186/s40560-018-0315-7

Similar Items